Oncternal Therapeutics Announces $6.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Read More
VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology Read More
Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia Read More
Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Read More
US FDA Allows Trial to Proceed for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP) Read More
Retrotope Initiates Project to Test RT001 in an Animal Model of Lung Damage to protect against COVID-19 impact Read More